TIRADS联合BRAFV600E 基因检测诊断意义不明确的 非典型病变或滤泡性病变的临床价值
DOI:
CSTR:
作者:
作者单位:

1.蚌埠医科大学研究生院;2.中国科学技术大学附属第一医院(安徽省立医院)超声医学科

作者简介:

通讯作者:

中图分类号:

基金项目:


Clinical value of TIRADS combined with BRAFV600E gene testing in diagnosing atypical or follicular lesions of undetermined significance
Author:
Affiliation:

Graduate School of Bengbu Medical University

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨甲状腺影像报告和数据系统(TIRADS)联合BRAFV600E基因检测在诊断甲状腺意义不明确的非典型病变或滤泡性病变(AUS/FLUS)中的临床价值。方法 选取行甲状腺细针穿刺活检并经细胞病理学诊断为AUS/FLUS,经手术病理确诊的甲状腺结节患者(221例,共223个结节),所有结节均行超声检查并进行C-TIRADS、ACR-TIRADS分类,同时行BRAFV600E基因检测。以术后病理结果为金标准,绘制受试者工作特征(ROC)曲线分析各方法单独及联合应用诊断AUS/FLUS良恶性的效能。结果 纳入的223个结节中,恶性结节165个,良性结节58个。ROC曲线分析显示,BRAFV600E基因检测、C-TIRADS、ACR-TIRADS单独应用诊断AUS/FLUS良恶性的AUC、灵敏度、特异度、准确率分别为0.852、73.94%、96.55%、79.82%;0.880、67.27%、98.28%、75.34%;0.843、85.45%、79.31%、83.86%;C-TIRADS联合BRAFV600E基因检测的AUC、灵敏度、特异度、准确率分别为0.950、90.91%、96.55%、88.3%;ACR-TIRADS联合BRAFV600E基因检测的AUC、灵敏度、特异度、准确率分别为0.937、95.76%、79.31%、82.96%。BRAFV600E检测联合C-TIRADS较单一BRAFV600E或单一C-TIRADS在不明显降低特异性的基础上,敏感性和准确性均显著提高(P均<0.05);BRAFV600E检测联合ACR-TIRADS诊断AUS/FLUS的敏感性较单一BRAFV600E检测或单一ACR-TIRADS明显提高(P均<0.001)。结论 TIRADS联合BRAFV600E基因检测对AUS/FLUS具有良好的诊断效能,有一定的临床价值。

    Abstract:

    Objective To evaluate the clinical value of combining the Thyroid Imaging Reporting and Data System (TIRADS) with BRAFV600E gene mutation testing in diagnosing atypical or follicular lesions of undetermined significance (AUS/FLUS) in thyroid nodules. Methods Patients with thyroid nodules (221 cases, 223 nodules) who underwent fine-needle aspiration biopsy and were cytopathologically diagnosed as AUS/FLUS, with surgical pathological confirmation, were selected. All nodules underwent ultrasound examination and were classified according to C-TIRADS and ACR-TIRADS, along with BRAFV600E gene mutation testing. Using postoperative pathological results as the gold standard, receiver operating characteristic (ROC) curves were plotted to analyze the diagnostic performance of each method individually and in combination for distinguishing benign and malignant AUS/FLUS lesions. Results Among the 223 nodules included, 165 were malignant and 58 were benign. ROC curve analysis revealed that the AUC, sensitivity, specificity, and accuracy of BRAFV600E gene mutation testing, C-TIRADS, and ACR-TIRADS alone for diagnosing benign and malignant AUS/FLUS were 0.852, 73.94%, 96.55%, 79.82%; 0.880, 67.27%, 98.28%, 75.34%; and 0.843, 85.45%, 79.31%, 83.86%, respectively. The combination of C-TIRADS and BRAFV600E testing yielded an AUC, sensitivity, specificity, and accuracy of 0.950, 90.91%, 96.55%, and 88.3%, respectively, while the combination of ACR-TIRADS and BRAFV600E testing resulted in 0.937, 95.76%, 79.31%, and 82.96%, respectively. The combination of BRAFV600E testing and C-TIRADS significantly improved sensitivity and accuracy without significantly reducing specificity compared to BRAFV600E or C-TIRADS alone (P < 0.05). Similarly, the combination of BRAFV600E testing and ACR-TIRADS significantly enhanced sensitivity compared to BRAFV600E or ACR-TIRADS alone (P < 0.001). Conclusion The combination of TIRADS and BRAFV600E gene mutation testing demonstrates strong diagnostic performance for AUS/FLUS, offering significant clinical value.

    参考文献
    相似文献
    引证文献
引用本文

李娟,刘潇,叶显俊. TIRADS联合BRAFV600E 基因检测诊断意义不明确的 非典型病变或滤泡性病变的临床价值[J].临床超声医学杂志,2025,27(4):327-331

复制
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-08-13
  • 最后修改日期:2025-03-17
  • 录用日期:2024-09-20
  • 在线发布日期: 2025-04-30
  • 出版日期:
文章二维码

扫码关注

官方微信